| Identification | Back Directory | [Name]
AKT-IN-3 | [CAS]
2374740-21-1 | [Synonyms]
AKT-IN-3
AKT IN 3,AKTIN3
2-Piperidineacetamide, 5-[[[5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furanyl]carbonyl]amino]-4-(3,4-difluorophenyl)-N-methyl-, (2S,4S,5S)- | [Molecular Formula]
C23H23Cl2F2N5O3 | [MDL Number]
MFCD32197239 | [MOL File]
2374740-21-1.mol | [Molecular Weight]
526.36 |
| Chemical Properties | Back Directory | [Boiling point ]
672.8±55.0 °C(Predicted) | [density ]
1.54±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
12.67±0.60(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells[1]. | [IC 50]
Akt1: 1.4 nM (IC50); Akt2: 1.2 nM (IC50); Akt3: 1.7 nM (IC50); PKA: 0.3 nM (IC50); P70S6K: 8.9 (IC50) | [References]
[1] Dong X, et al. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem. 2019 Aug 8;62(15):7264-7288. DOI:10.1021/acs.jmedchem.9b00891 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|